Javascript must be enabled to continue!
Evaluation of the neuroprotective effect of donepezil in type 2 diabetic rats
View through CrossRef
AbstractRecent studies raise the possibility that donepezil can delay the progression of Alzheimer’s disease (AD). This research evaluated the efficacy of donepezil in an animal model with brain insulin resistance and AD‐like alterations. Rats were fed with high‐fat/high‐fructose (HF/Hfr) diet during the study period (17 weeks) and received one injection of streptozotocin (STZ) (25 mg/kg) after 8 weeks of starting the study. Diabetic (T2D) rats were treated with donepezil (4 mg/kg; p.o.) or vehicle for 8 weeks after STZ injection. The influence of donepezil on AD‐related behavioral, biochemical, and neuropathological changes was investigated in T2D rats. Treatment of diabetic rats with donepezil led to a significant decrease in both amyloid‐β deposition and the raised hippocampal activity of cholinesterase (ChE). It significantly increased the suppressed glutamate receptor expression (AMPA GluR1 subunit and NMDA receptor subunits NR1, NR2A, NR2B). It also improved cognitive dysfunction in the passive avoidance and the Morris water maze tests. However, donepezil treatment did not significantly decrease the elevated levels of P‐tau, caspase‐3, GSK‐3β, MDA, TNF‐α, and IL‐1β in the hippocampus of diabetic rats. Also, it did not restore the suppressed levels of glutathione and superoxide dismutase in the brain of these rats. Moreover, donepezil did not alter the elevated serum level of glucose, insulin, and total cholesterol. These findings suggest that donepezil treatment could ameliorate learning and memory impairment in T2D rats through reversal of some of the AD‐related alterations, including reduction of amyloid‐β burden and ChE activity as well as restoration of glutamate receptor expression. However, lack of any significant effect on P‐tau load, oxidative stress, neuroinflammation, and insulin resistance raises the question about the ability of donepezil to delay the development or arrest the progression of T2D‐induced AD and it is still a matter of debate that requires further studies.
Title: Evaluation of the neuroprotective effect of donepezil in type 2 diabetic rats
Description:
AbstractRecent studies raise the possibility that donepezil can delay the progression of Alzheimer’s disease (AD).
This research evaluated the efficacy of donepezil in an animal model with brain insulin resistance and AD‐like alterations.
Rats were fed with high‐fat/high‐fructose (HF/Hfr) diet during the study period (17 weeks) and received one injection of streptozotocin (STZ) (25 mg/kg) after 8 weeks of starting the study.
Diabetic (T2D) rats were treated with donepezil (4 mg/kg; p.
o.
) or vehicle for 8 weeks after STZ injection.
The influence of donepezil on AD‐related behavioral, biochemical, and neuropathological changes was investigated in T2D rats.
Treatment of diabetic rats with donepezil led to a significant decrease in both amyloid‐β deposition and the raised hippocampal activity of cholinesterase (ChE).
It significantly increased the suppressed glutamate receptor expression (AMPA GluR1 subunit and NMDA receptor subunits NR1, NR2A, NR2B).
It also improved cognitive dysfunction in the passive avoidance and the Morris water maze tests.
However, donepezil treatment did not significantly decrease the elevated levels of P‐tau, caspase‐3, GSK‐3β, MDA, TNF‐α, and IL‐1β in the hippocampus of diabetic rats.
Also, it did not restore the suppressed levels of glutathione and superoxide dismutase in the brain of these rats.
Moreover, donepezil did not alter the elevated serum level of glucose, insulin, and total cholesterol.
These findings suggest that donepezil treatment could ameliorate learning and memory impairment in T2D rats through reversal of some of the AD‐related alterations, including reduction of amyloid‐β burden and ChE activity as well as restoration of glutamate receptor expression.
However, lack of any significant effect on P‐tau load, oxidative stress, neuroinflammation, and insulin resistance raises the question about the ability of donepezil to delay the development or arrest the progression of T2D‐induced AD and it is still a matter of debate that requires further studies.
Related Results
Steady‐State Plasma Concentration of Donepezil Enantiomers and Its Stereoselective Metabolism and Transport In Vitro
Steady‐State Plasma Concentration of Donepezil Enantiomers and Its Stereoselective Metabolism and Transport In Vitro
ABSTRACTThe aim of the present study was to elucidate the differences in the plasma concentration of two enantiomers of donepezil in Chinese patients with Alzheimer's disease (AD) ...
Platform Session B: Clinical Neurophysiology/Clinical Epilepsy
3:00 p.m.–6:00 p.m.
Platform Session B: Clinical Neurophysiology/Clinical Epilepsy
3:00 p.m.–6:00 p.m.
1
Jose F.
Tellez‐Zenteno,
1
Scott B.
Patten, and
1
Samuel
Wiebe
...
Donepezil-induced psychosis: a cautionary report of a rare adverse reaction
Donepezil-induced psychosis: a cautionary report of a rare adverse reaction
IntroductionDonepezil is an acetylcholinesterase inhibitor approved by the Food and Drug Administration for the treatment of dementia in Alzheimer’s disease. While it is not curati...
Acetylcholinesterase inhibitor protects against cardiac ischaemia/reperfusion injury via enhancing mitophagy and rebalancing mitochondrial dynamics
Acetylcholinesterase inhibitor protects against cardiac ischaemia/reperfusion injury via enhancing mitophagy and rebalancing mitochondrial dynamics
Abstract
Background
Ischaemic heart disease is the most common cause of death globally. Although reperfusion therapy is essentia...
Safety and Tolerability of Donepezil in Mild Cognitive Impairment: Open-Label Extension Study
Safety and Tolerability of Donepezil in Mild Cognitive Impairment: Open-Label Extension Study
Following a 48-week, double-blind, randomized, placebo-controlled trial of donepezil in 821 patients with amnestic mild cognitive impairment (aMCI), safety and tolerability of done...
Evaluation of the Combined Therapeutic Potential of Turmeric and Donepezil on the Cholinergic System in a Mouse Model of AD-like Pathology
Evaluation of the Combined Therapeutic Potential of Turmeric and Donepezil on the Cholinergic System in a Mouse Model of AD-like Pathology
Introduction:
The multifactorial pathogenesis of Alzheimer’s Disease (AD) makes effective
prevention and treatment challenging. Integrative medicine presents a ...
Dose-dependent dissociation of pro-cognitive effects of donepezil on attention and cognitive flexibility in rhesus monkeys
Dose-dependent dissociation of pro-cognitive effects of donepezil on attention and cognitive flexibility in rhesus monkeys
ABSTRACTBACKGROUNDDonepezil exerts pro-cognitive effects by non-selectively enhancing acetylcholine (ACh) across multiple brain systems. The brain systems that mediate pro-cognitiv...
Protective Effects of Aqueous Extract of Carica papaya Leaf on the Liver of Streptozotocin (STZ)-Induced Diabetic Adult Wistar Rats
Protective Effects of Aqueous Extract of Carica papaya Leaf on the Liver of Streptozotocin (STZ)-Induced Diabetic Adult Wistar Rats
Carica papaya Linn. (Family: Caricaceae) is a perennial, herbaceous plant used traditionally among the Yoruba tribe of Nigeria for the treatment of various human and veterinary dis...

